Previous 10 | Next 10 |
Axonics Modulation Technologies, Inc. (AXNX) Q3 2020 Earnings Conference Call October 4, 2020 4:20 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Participants David Lew...
Gainers: [[ALTM]] +54.6%. [[UPWK]] +24.6%. [[QCOM]] +13.2%. [[APHA]] +10.1%. [[MTW]] +9.5%.Losers: [[BLUE]] -13.9%. [[ELF]] -9.4%. [[INGN]] -8.9%. [[AXNX]] -8.7%. [[PING]] -8.7%. For further details see: ALTM, UPWK, AXNX and INGN among after-hours movers
Axonics Modulation Technologies (AXNX): Q3 GAAP EPS of -$0.24 beats by $0.31.Revenue of $35.2M (+2587.0% Y/Y) beats by $12.25M.Shares -6.8%.Press Release For further details see: Axonics Modulation Technologies EPS beats by $0.31, beats on revenue
Axonics generated net revenue of $35.2 million in the third quarter ended September 30, 2020 Over 5,500 patients have been implanted with the Axonics r-SNM System since U.S. commercial launch Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical tec...
Axonics Modulation Technologies (AXNX) submits a supplemental premarket approval ((PMA)) to the FDA, detachable extremity coil magnetic resonance imaging ((MRI)) conditional labeling for 1.5T and 3.0T MR scanners.The FDA previously approved 1.5T and 3.0T MRI conditional labeling with hea...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has submitted a premarket approval (PMA) supplement to ...
ARTISTRY will enroll up to 300 patients across 30 centers in North America and include patients across all four clinical indications for Axonics Therapy Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializi...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report third quarter 2020 financial results and pr...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, today announced that Raymond W. Cohen, CEO of Axonics, has be...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced survey results of 137 patients previous...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...
2024-06-19 23:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-29 07:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...